Activity of veltuzumab, a second-generation humanized anti-CD20 mAb, in laboratory and clinical studies

被引：0
|
作者：
Goldenberg, D. M. [2 ]
Chang, C. [6 ]
Rossi, E. A. [6 ]
Cardillo, T. M. [6 ]
Wegener, W. A. [6 ]
Teoh, N. [6 ]
Leonard, J. P. [5 ]
Fayad, L. [4 ]
Coiffier, B. [3 ]
Morschhauser, F. [1 ]
机构：
[1] Ctr Hosp Reg & Univ Lille, Serv Malad Sang, F-59037 Lille, France
[2] Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ USA
[3] Ctr Hosp Lyon Sud, Serv Hematol, Lyon, France
[4] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, New York, NY 10021 USA
[6] Res & Dev Immunomedics Inc, Morris Plains, NJ USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [41] Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope
    Uchiyama, Susumu
    Suzuki, Yasuhiko
    Otake, Kentaro
    Yokoyama, Masami
    Ohta, Mitsuo
    Aikawa, Shuichi
    Komatsu, Midori
    Sawada, Tetsuji
    Kagami, Yoshitoyo
    Morishima, Yasuo
    Fukui, Kiichi
    [J]. CANCER SCIENCE, 2010, 101 (01) : 201 - 209
  • [42] Dysregulation of the cell survival/anti-apoptotic NF-κB pathway by the novel humanized BM-ca anti-CD20 mAb: Implication in chemosensitization
    Vega, Mario I.
    Martinez-Paniagua, Melisa
    Huerta-Yepez, Sara
    Gonzalez-Bonilla, Cesar
    Uematsu, Norio
    Bonavida, Benjamin
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 35 (06) : 1289 - 1296
  • [43] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
    Cartron, G
    Dacheux, L
    Salles, G
    Solal-Celigny, P
    Bardos, P
    Colombat, P
    Watier, H
    [J]. BLOOD, 2002, 99 (03) : 754 - 758
  • [44] Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations
    Weisman, Leonard E.
    [J]. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2009, 11 (02) : 208 - 216
  • [45] Role of neutrophils in the activity of therapeutic anti-CD20 MAbs
    Golay, J.
    Da Roit, F.
    Bologna, L.
    Ferrara, C.
    Leusen, J.
    Rambaldi, A.
    Klein, C.
    Introna, M.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 : 18 - 19
  • [46] Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
    Cragg, MS
    Morgan, SM
    Chan, HTC
    Morgan, BP
    Filatov, AV
    Johnson, PWM
    French, RR
    Glennie, MJ
    [J]. BLOOD, 2003, 101 (03) : 1045 - 1052
  • [47] Generation of a Potent Recombinant Homophilic Chimeric Anti-CD20 Antibody
    Kohler, Heinz
    Rector, Kyle
    Amick, Jean
    [J]. HYBRIDOMA, 2012, 31 (06): : 395 - 402
  • [48] Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia
    Liebman, Howard A.
    Saleh, Mansoor N.
    Bussel, James B.
    Bernstein, Zale P.
    Negrea, O. George
    Onyegbula, Anthony C.
    Farber, Charles M.
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    [J]. BLOOD, 2011, 118 (21) : 1420 - 1420
  • [49] Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs
    Huang, Deren
    Alvarez, Enrique
    Miskin, Hari
    Lee, Lily
    Foley, John
    [J]. NEUROLOGY, 2023, 100 (17)
  • [50] MAb Therapy:: the use of anti-CD20 Abs -: In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs
    Derigs, HG
    [J]. CYTOTHERAPY, 2000, 2 (06) : 445 - 453
12345